# Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer

> **NCT02562118** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 40 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Lenvatinib + Letrozole

## Key facts

- **NCT ID:** NCT02562118
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-10-02
- **Primary completion:** 2027-01
- **Final completion:** 2027-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02562118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02562118, "Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02562118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*